Marco Sanduzzi-Zamparelli

12PUBLICATIONS
64CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Health promotionInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Feb 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo

|Aug 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.

Marta Fortuny, Leonardo G da Fonseca, Manon Allaire

|Mar 14, 2025
Surveillance in HCC: Making the Most of What We Have Today.

Marco Sanduzzi-Zamparelli, Giuseppe Cabibbo

|Dec 10, 2024
The "shell game" after objective response in patients with advanced HCC treated with immunotherapy.

Marco Sanduzzi-Zamparelli, Giuseppe Cabibbo

|Jan 24, 2024
Systemic therapies in hepatocellular carcinoma: A revolution?

Marta Fortuny, Marco Sanduzzi-Zamparelli, Maria Reig

|Jan 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.

Ismael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena

Pageof 2